PVLA

Palvella Therapeutics (PVLA)

About Palvella Therapeutics (PVLA)

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

Details

Daily high

$160.21

Daily low

$156.09

Price at open

$159.00

52 Week High

$161.38

52 Week Low

$38.95

Market cap

2.2B

Dividend yield

0.00%

Volume

182,299

Avg. volume

211,951

P/E ratio

-37.16

Palvella Therapeutics News